Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation

Fig. 1

Timeline depicting the patient’s clonal evolution, treatment regimens, and responses since diagnosis. Timeline is represented in days since the establishment of MM diagnosis. Treatment regimens are indicated with black arrows descending toward the upper side of the timeline. Diagnostic whole-exome sequencing (WES), RNA-sequencing (RNA-seq) or targeted panel are indicated as blue bars descending from the timeline. Red arrows indicate period of disease progression (PD), and different shades of green arrows indicate very good partial response (VGPR), complete response (CR), and stringent complete response (sCR). Lower part of the graph depicts the patient’s lambda LC levels (mg/L) since the beginning of the triple therapy regimen (regorafenib, dabrafenib and encorafenib) until sCR achieved after antibody trial 2. ASCT: Autologous stem cell transplantation; VCd: Velcade (Bortezomib), cyclophosphamide and dexamethasone. VRd: Velcade (Bortezomib), lenalidomide, and dexamethasone; Vd: Velcade (Bortezomib) and dexamethasone; anti-BCMA CAR-T: anti-B cell maturation antigen chimeric antigen receptor T cells; VDCEP: Velcade (Bortezomib), dexamethasone, cyclophosphamide, etoposide, and cisplatin; BCNU: Carmustine

Back to article page